Despite the poor prognosis of CRC cases with an established BRAF V600E mutation, the potential of a new therapeutic strategy with a combination of encorafenib and cetuximab has been demonstrated, which significantly increases overall survival without compromising the quality of life [10]. The gene discussed is BRAF; the disease is colorectal carcinoma.